ClinicalTrials.gg

Program

remternetug

Also written as “LY3372993”, “Remternetug” and “Remternetug (IV)”.

Its studies are mostly in Alzheimer Disease, led by Eli Lilly.

Furthest: phase 3, since Jul 14, 20226 company-led studies, 1 open or runningNext primary completion: Apr 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly61 open or runningphase 3since Jul 14, 2022Oct 24, 2018Apr 2029phase 3 · NCT06653153
  • Named in Eli Lilly’s own pipeline as Remternetug, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 24, 2018First study: phase 1 study in Alzheimer DiseaseFirst studyNCT03720548 · 36 enrolled · United States
  2. Jun 26, 2020Phase 1 study in Alzheimer DiseaseNCT04451408 · 139 enrolled · United States, Japan
  3. Jul 14, 2022Phase 3 study in Alzheimer DiseaseNCT05463731 · 1,667 enrolled · United States, Japan
  4. Oct 21, 2024Phase 3 study in Alzheimer DiseaseNCT06653153 · 1,400 enrolled · United States, Australia, Canada and more
  5. Jun 24, 2025Phase 1 study in HealthyNCT07056309 · 72 enrolled · United States
  6. Jan 9, 2026Phase 1 study in HealthyNCT07346495 · 24 enrolled · China

Ahead

  1. Apr 2029Primary completion: phase 3 study in Alzheimer DiseaseNCT06653153

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07346495Healthy · China1CompletedAug 4, 202624
NCT07056309Healthy · United States1CompletedDec 15, 202572
NCT06653153Alzheimer Disease · United States, Australia, Canada and more3Active, not recruitingApr 20291,400
NCT05463731Alzheimer Disease · United States, Japan3CompletedApr 24, 20241,667
NCT04451408Alzheimer Disease · United States, Japan1CompletedNov 18, 2024139
NCT03720548Alzheimer Disease · United States1CompletedMay 14, 201936

How it is read

Names in the registry

  • “LY3372993”, 3 entries
  • “Remternetug”, 1 entry
  • “Remternetug (IV)”, 1 entry
  • “Remternetug (SC)”, 1 entry
  • “Remternetug (Test)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.